Purchase Order 36C26024P0883

Award Date 7/25/24
Potential Completion Date 9/30/24
Potential Value $117K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Orlando, FL 32824, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price purchase order awarded by the U.S. Department of Veterans Affairs (VA) to Profounda Inc., a self-certified small disadvantaged business and manufacturer of pharmaceutical products. The contract, valued at $99,900.00, is for the delivery of Miltefosine 50mg tablets, a critical medication used to treat leishmaniasis and other drug-resistant infections. This purchase order is part of a larger $1,127,000 Blanket Purchase Agreement (BPA) held by Profounda Inc. with the VA's...
This is a firm fixed-price purchase order contract awarded by the U.S. Department of Veterans Affairs (VA) to Profounda Inc., a self-certified small disadvantaged business and manufacturer of pharmaceutical products. The contract, valued at $49,950.00, is for the delivery of Impavido/Miltefosine, a critical medication used to treat leishmaniasis and other drug-resistant infections, to VA medical centers within the Veterans Integrated Service Network 20 (VISN 20). Profounda Inc. holds a...
This is a firm fixed-price purchase order awarded by the U.S. Department of Veterans Affairs (VA) to Profounda Inc., a self-certified small disadvantaged business and manufacturer of pharmaceutical products. The contract, valued at $33,300.00, is for the delivery of Impavido/Miltefosine, a critical medication used to treat leishmaniasis and other drug-resistant infections. The contract has an ultimate completion date of January 8, 2025. Profounda Inc. has a significant Blanket Purchase Agreement...
The Department of Veterans Affairs' Veterans Health Administration awarded a firm fixed-price purchase order to Profounda Inc., a self-certified small disadvantaged business, to provide Miltefosine drug with a potential value of $149,950.00. The order, placed under the VHA's Veterans Integrated Service Network 23, supports the agency's mission to deliver healthcare services to veterans by ensuring access to this specialized pharmaceutical product needed for treatment. Profounda has previously...
This is a firm fixed-price purchase order awarded by the U.S. Department of Veterans Affairs (VA) Veterans Integrated Service Network (VISN) 23 to Profounda Inc., a self-certified small disadvantaged business and manufacturer of pharmaceutical products. The $49,950.00 contract is for the delivery of the emergency medication miltefosine (Impavido) to the Minneapolis VA Medical Center. Profounda Inc. has a significant Blanket Purchase Agreement (BPA) with VISN 8 to provide miltefosine on a...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 23 awarded a $16,750 purchase order to Profounda Inc. for the delivery of 50mg miltefosine capsules. The firm fixed price contract runs from December 14, 2023 through January 13, 2024 and will be performed in Omaha, Nebraska. Profounda Inc. will provide the pharmaceutical products to VA-VHA under this contract to support their healthcare services for veterans. No subcontractors or set aside...
The U.S. Department of Veterans Affairs (VA) Veterans Health Administration awarded a $299,700.00 firm fixed-price purchase order to Profounda Inc., a self-certified small disadvantaged business manufacturer of pharmaceutical products, to provide the medication Impavido (miltefosine) to the Puget Sound VA Medical Center. This sole-source procurement is to acquire this specialized drug for treating Disseminated Cutaneous Acanthamboeba, with a performance period from May 1, 2025, to October 30,...
This is a $10,162.71 firm fixed-price purchase order contract awarded by the Department of Veterans Affairs (VA) to All-Med, Inc., a self-certified small disadvantaged, veteran-owned, service-disabled veteran-owned business. The contract, which has no set-aside designation, is for the provision of prosthetics and has an ultimate completion date of July 21, 2025. The contract was awarded on July 22, 2024 and is part of the VA's Veterans Integrated Service Network 20 (VISN 20) program, which...
This is a $19,253.08 firm-fixed-price purchase order awarded by the Veterans Integrated Service Network 19 (VISN 19) of the U.S. Department of Veterans Affairs (VA) to Milspec Logistics LLC, a service-disabled veteran-owned small business (SDVOSB). The contract is for the supply of prosthetic implants. As a prime contractor, Milspec Logistics has experience providing logistical support services to federal agencies, including the VA, for hazardous materials handling, waste disposal,...
This is a $132,222 firm fixed-price purchase order awarded by the Department of Veterans Affairs to United Drug Supply Inc., a woman-owned small business. The contract is not set aside. United Drug Supply Inc. specializes in providing medical supplies and equipment to the federal government, primarily the Department of Defense and Department of Veterans Affairs. The contract involves the delivery of various medical consumables, diagnostic devices, and pharmaceutical products to support...

This is a firm fixed-price purchase order awarded by the Department of Veterans Affairs' (VA) Veterans Health Administration (VHA) to Profounda Inc., a self-certified small disadvantaged business and manufacturer. The $116,550 contract is for the delivery of Miltefosine, a medication used to treat leishmaniasis and other drug-resistant infections in veterans. The contract has an ultimate completion date of September 30, 2024 and is part of a larger $1,127,000 Blanket Purchase Agreement (BPA) that Profounda holds with the VHA's Veterans Integrated Service Network 8 (VISN 8). This BPA enables Profounda to pre-position its Miltefosine product at VA medical centers within VISN 8, ensuring expedited access and treatment for urgent cases. The contract does not utilize any set-aside designations.

Generated 7/25/24, 9:47 AM